Review
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
Affiliations
- PMID: 25425467
Item in Clipboard
Review
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
Discov Med.
2014 Nov.
Free article
Abstract
Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy.
Similar articles
-
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Cytotherapy. 2016 Nov;18(11):1393-1409. doi: 10.1016/j.jcyt.2016.07.003. Epub 2016 Aug 31. Cytotherapy. 2016. PMID: 27592405 Free PMC article. Review.
-
Establishing guidelines for CAR-T cells: challenges and considerations.Sci China Life Sci. 2016 Apr;59(4):333-9. doi: 10.1007/s11427-016-5026-5. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26965523 Review.
-
Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?Biochem Soc Trans. 2016 Apr 15;44(2):406-11. doi: 10.1042/BST20150286. Biochem Soc Trans. 2016. PMID: 27068947 Review.
-
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009942 Free PMC article. Review.
-
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9. Med Oncol. 2018. PMID: 29730801 Review.
Cited by
-
New approaches for the immunotherapy of acute myeloid leukemia.Discov Med. 2015 Apr;19(105):275-84. Discov Med. 2015. PMID: 25977190 Free PMC article. Review.
-
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.J Hematol Oncol. 2018 Mar 20;11(1):44. doi: 10.1186/s13045-018-0591-7. J Hematol Oncol. 2018. PMID: 29558951 Free PMC article.
-
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis.Cancers (Basel). 2019 Jan 7;11(1):47. doi: 10.3390/cancers11010047. Cancers (Basel). 2019. PMID: 30621018 Free PMC article. Review.
-
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.J Immunol Res. 2016;2016:4273943. doi: 10.1155/2016/4273943. Epub 2016 Dec 26. J Immunol Res. 2016. PMID: 28116316 Free PMC article. Review.
-
Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan. Eng Life Sci. 2020. PMID: 33531889 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
